Conference abstract SL-28

**Absolute Bioavailability and Metabolism of Dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides (“tetraene”) after Intravenous and Oral Single Doses to Rats**

K. WÖLKART 1,3, R. FRYE 2, H. DERENDORF 1, R. BAUER 3, V. BUTTERWECK 1

1 Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida 32610, USA
2 Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, Florida 32610, USA
3 Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl-Franzens-University Graz, 8010 Graz, Austria

E-mail: ka.woelkart@uni-graz.at (K. Wölkart)


This study assessed the absolute and relative bioavailabilities of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides (tetraene), one of the main bioactive constituents in *Echinacea*, administered as pure compounds or as an *Echinacea purpurea* root extract preparation. Ten rats received 0.75 mg/kg dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides oral, pure and within 158.6 mg/kg *Echinacea purpurea* extract, or intravenous. Pharmacokinetic parameters and bioavailability data of tetraene were obtained by non-compartmental analysis using WinNonlin® 5.2 software. Mean dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamide plasma area under the concentration-time curve (AUC_{0-∞}/Dose) was 3.2 ± 0.3 min*ng/mL/µg and 1.0 ± 0.2 min*ng/mL/µg after iv and oral administration, respectively, and 1.5 ± 0.2 min*ng/mL/µg after oral administration of the *Echinacea* root extract. The absolute and relative bioavailability of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides were 29 % and 47 %, respectively. Administration of a whole *Echinacea* extract increases blood exposure with no impact on C_{max}. The high area under the curve concentration resulted in a longer elimination half-life with 123 min in comparison to 36 min after administration of the pure dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides. A rapid absorption followed by a slower elimination phase was observed.

Presented at the 21st Scientific Congress of the Austrian Pharmaceutical Society April 16th to April 18th 2009, Vienna, Austria.